Literature DB >> 19492422

A novel osteoclast precursor cell line, 4B12, recapitulates the features of primary osteoclast differentiation and function: enhanced transfection efficiency before and after differentiation.

Shigeru Amano1, Keisuke Sekine, Lynda F Bonewald, Yoshihiro Ohmori.   

Abstract

Osteoclasts are bone-resorbing multinucleated cells differentiated from monocyte/macrophage lineage precursors. A novel osteoclast precursor cell line, 4B12 was established from Mac-1(+)c-Fms(+)RANK(+) cells from calvaria of 14-day-old mouse embryos using immunofluorescence and cell-sorting methods. Like M-CSF-dependent bone marrow macrophages (M-BMMs), M-CSF is required for 4B12 cells to differentiate into TRAP-positive multinucleated cells [TRAP(+) MNCs] in the presence of RANKL. Bone-resorbing osteoclasts differentiated from 4B12 cells on dentine slices possess both a clear zone and ruffled borders and express osteoclast-specific genes. Bone-resorbing activity, but not TRAP, was enhanced in the presence of IL-1alpha. The number of TRAP(+) MNCs and the number of pits formed from 4B12 cells on dentine slices was fourfold higher than that from M-BMMs. 4B12 cells were identified as macrophages with Mac-1 and F4/80, yet lost these markers upon differentiation into osteoclasts as determined by confocal laser scanning microscopy. The 4B12 cells do not have the potential to differentiate into dendritic cells indicating commitment to the osteoclast lineage. 4B12 cells are readily transfectable with siRNA transfection before and after differentiation. These data show that 4B12 cells faithfully replicate the properties of primary cells and are a useful and powerful model for analyzing the molecular and cellular regulatory mechanisms of osteoclastogenesis and osteoclast function. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19492422      PMCID: PMC4080882          DOI: 10.1002/jcp.21827

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  49 in total

1.  Development of osteoclasts from embryonic stem cells through a pathway that is c-fms but not c-kit dependent.

Authors:  T Yamane; T Kunisada; H Yamazaki; T Era; T Nakano; S I Hayashi
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

2.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

3.  Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2KbtsA58 transgenic mouse.

Authors:  T J Chambers; J M Owens; G Hattersley; P S Jat; M D Noble
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

4.  Postmitotic osteoclast precursors are mononuclear cells which express macrophage-associated phenotypes.

Authors:  N Takahashi; N Udagawa; S Tanaka; H Murakami; I Owan; T Tamura; T Suda
Journal:  Dev Biol       Date:  1994-05       Impact factor: 3.582

5.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Authors:  D M Anderson; E Maraskovsky; W L Billingsley; W C Dougall; M E Tometsko; E R Roux; M C Teepe; R F DuBose; D Cosman; L Galibert
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

6.  Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo.

Authors:  Ming K Chang; Liza-Jane Raggatt; Kylie A Alexander; Julia S Kuliwaba; Nicola L Fazzalari; Kate Schroder; Erin R Maylin; Vera M Ripoll; David A Hume; Allison R Pettit
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

7.  In vitro differentiation of the murine macrophage cell line BDM-1 into osteoclast-like cells.

Authors:  J H Shin; A Kukita; K Ohki; T Katsuki; O Kohashi
Journal:  Endocrinology       Date:  1995-10       Impact factor: 4.736

8.  Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors.

Authors:  S Tanaka; N Takahashi; N Udagawa; T Tamura; T Akatsu; E R Stanley; T Kurokawa; T Suda
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

9.  Expression of Mac-2 antigen in the preosteoclast and osteoclast identified in the op/op mouse injected with macrophage colony-stimulating factor.

Authors:  S Niida; N Amizuka; F Hara; H Ozawa; H Kodama
Journal:  J Bone Miner Res       Date:  1994-06       Impact factor: 6.741

10.  Phorbol ester induced osteoclast-like differentiation of a novel human leukemic cell line (FLG 29.1).

Authors:  V Gattei; P A Bernabei; A Pinto; R Bezzini; A Ringressi; L Formigli; A Tanini; V Attadia; M L Brandi
Journal:  J Cell Biol       Date:  1992-01       Impact factor: 10.539

View more
  8 in total

1.  Fe3O4 Magnetic Nanoparticles Under Static Magnetic Field Improve Osteogenesis via RUNX-2 and Inhibit Osteoclastogenesis by the Induction of Apoptosis.

Authors:  Krzysztof Marycz; Paulina Sobierajska; Rafał J Wiglusz; Rafał Idczak; Jean-Marie Nedelec; Andrzej Fal; Katarzyna Kornicka-Garbowska
Journal:  Int J Nanomedicine       Date:  2020-12-14

2.  Impact of Polyrhodanine Manganese Ferrite Binary Nanohybrids (PRHD@MnFe2O4) on Osteoblasts and Osteoclasts Activities-A Key Factor in Osteoporosis Treatment.

Authors:  Krzysztof Marycz; Anna Kowalczuk; Eliza Turlej; Emilia Zachanowicz; Anna Tomaszewska; Magdalena Kulpa-Greszta; Martyna Kępska; Zofia Steczkiewicz; Robert Pązik
Journal:  Materials (Basel)       Date:  2022-06-03       Impact factor: 3.748

3.  ERK5 activation is essential for osteoclast differentiation.

Authors:  Shigeru Amano; Yu-Tzu Chang; Yasuhisa Fukui
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

4.  Iron oxides nanoparticles (IOs) exposed to magnetic field promote expression of osteogenic markers in osteoblasts through integrin alpha-3 (INTa-3) activation, inhibits osteoclasts activity and exerts anti-inflammatory action.

Authors:  K Marycz; P Sobierajska; M Roecken; K Kornicka-Garbowska; M Kępska; R Idczak; J-M Nedelec; R J Wiglusz
Journal:  J Nanobiotechnology       Date:  2020-02-18       Impact factor: 10.435

5.  Novel Nanohydroxyapatite (nHAp)-Based Scaffold Doped with Iron Oxide Nanoparticles (IO), Functionalized with Small Non-Coding RNA (miR-21/124) Modulates Expression of Runt-Related Transcriptional Factor 2 and Osteopontin, Promoting Regeneration of Osteoporotic Bone in Bilateral Cranial Defects in a Senescence-Accelerated Mouse Model (SAM/P6). PART 2.

Authors:  Krzysztof Marycz; Agnieszka Śmieszek; Katarzyna Kornicka-Garbowska; Ariadna Pielok; Maciej Janeczek; Anna Lipińska; Anna Nikodem; Jarosław Filipiak; Paulina Sobierajska; Jean-Marie Nedelec; Rafał J Wiglusz
Journal:  Int J Nanomedicine       Date:  2021-08-31

6.  Nanohydroxyapatite (nHAp) Doped with Iron Oxide Nanoparticles (IO), miR-21 and miR-124 Under Magnetic Field Conditions Modulates Osteoblast Viability, Reduces Inflammation and Inhibits the Growth of Osteoclast - A Novel Concept for Osteoporosis Treatment: Part 1.

Authors:  Krzysztof Marycz; Agnieszka Smieszek; Klaudia Marcinkowska; Mateusz Sikora; Eliza Turlej; Paulina Sobierajska; Adrian Patej; Alina Bienko; Rafal J Wiglusz
Journal:  Int J Nanomedicine       Date:  2021-05-18

7.  Deficiency of the pattern-recognition receptor CD14 protects against joint pathology and functional decline in a murine model of osteoarthritis.

Authors:  Nisha Sambamurthy; Cheng Zhou; Vu Nguyen; Ryan Smalley; Kurt D Hankenson; George R Dodge; Carla R Scanzello
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

8.  The Role of miR-21 in Osteoblasts-Osteoclasts Coupling In Vitro.

Authors:  Agnieszka Smieszek; Klaudia Marcinkowska; Ariadna Pielok; Mateusz Sikora; Lukas Valihrach; Krzysztof Marycz
Journal:  Cells       Date:  2020-02-19       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.